arrow
J

Jole Ventriglia

istituto nazionale tumori di napoli irccs g. pascale
H指数:18
被引数:893
浏览量:0

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-World Analysis of Metastatic Renal Cell Carcinoma Patients Treated with Pembrolizumab Plus Axitinib: Evidence from the Campania Oncology Network

真实世界分析:接受帕博利珠单抗联合阿昔替尼治疗的转移性肾细胞癌患者——坎帕尼亚肿瘤网络证据

2026-05-310
OA
KELIM score: A marker of chemosensitivity in ovarian cancer

KELIM评分:卵巢癌化疗敏感性的标志物

2025-12-180
PRE
Time tO last ChemotherApy and death in ovaRian cancEr patients: TO CARE/MITO 42 study; a retrospective analysis of italian MITO centers

从末次化疗到死亡的时间在卵巢癌患者中的研究:TO CARE/MITO 42研究;一项意大利MITO中心的回顾性分析

2025-08-070
OA
The emerging role of PARP inhibitors in prostate cancer: A narrative review

PARP抑制剂在前列腺癌中的新兴作用:一篇叙述性综述

2025-07-250
OAAI
Olaparib as a rescue treatment in platinum-refractory germ-cell tumors: the IGG-02 phase II trial

奥拉帕利作为铂类耐药性生殖细胞肿瘤的挽救治疗:IGG-02期II临床试验

2025-05-010
PRE
Endometrial cancer in the elderly: Characteristics, prognostic and risk factors, and treatment options
2024-12-014
PRE
Efficacy of PARP inhibitors in advanced high-grade serous ovarian cancer according to BRCA domain mutations and mutation type

根据BRCA结构域突变和突变类型,PARP抑制剂在晚期高级别浆液性卵巢癌中的疗效

2024-09-093
OAAI
Complete and early response to cemiplimab associated to severe immune toxicity in advanced cervical cancer: a case report
2023-12-130
OAAI
The role of immunotherapy treatment in non-clear cell renal cell carcinoma: An analysis of the literature
2023-08-013
PRE
The way to precision medicine in gynecologic cancers: The first case report of an exceptional response to alpelisib in a PIK3CA-mutated endometrial cancer
2023-01-136
OAAI
Targeting immunometabolism mediated by the IDO1 Pathway: A new mechanism of immune resistance in endometrial cancer
2022-09-0214
OAAI
Is re-introduction or continuation of PARP inhibitors after local therapy for oligo-metastatic progression in patients with relapsed ovarian cancer relevant?
2022-09-012
OAAI
Immunotherapy in Penile Squamous Cell Carcinoma: Present or Future? Multi-Target Analysis of Programmed Cell Death Ligand 1 Expression and Microsatellite Instability
2022-05-0316
OAAI
Oligometastatic prostate cancer treatment
2021-07-232
PRE
Trabectedin in Ovarian Cancer: is it now a Standard of Care?

卵巢癌中的trabe tedin: 现在是护理标准吗?

2018-08-0115
PREAI
Systemic-inflammation-based score can predict prognosis in metastatic gastric cancer patients before first-line chemotherapy
2018-07-0315
PREAI
Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24)
2018-06-1447
PREAI
Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study
2018-03-2731
PREAI
Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives

卵巢癌,子宫内膜癌和宫颈癌的免疫治疗: 最新技术和未来展望

2017-09-01131
PREAI
Neutrophil to lymphocyte ratio is a predictor of outcome in metastatic pancreatic cancer patients (MPC) treated with nab-paclitaxel and gemcitabine
2016-10-010
OAAI